[ 메디채널 김갑성 기자 ] 광저우, 중국 2025년 10월 14일 -- 흔히 캔톤페어(Canton Fair)라고 불리는 제138회 중국수출입박람회(China Import and Export Fair)가 광저우에서 10월 15일부터 11월 4일까지 3단계로 나뉘어 진행된다. 캔톤페어는 전시장과 별도로 전 세계 바이어들이 언제 어디서든 중국 제조업체와 상담할 수 있도록 24시간 내내 온라인 운영 상태를 유지한다. 155만 제곱미터의 전시 면적에 7만 4600개의 부스가 마련되고 참가 기업이 3만 2000개를 넘을 정도로 이번 박람회는 역대 최대 규모를 자랑한다. 제138회 중국수출입박람회는 규모뿐 아니라 혁신 면에서도 기념비적인 행사이다. 사상 처음으로, '중국 첨단 기술 회사(National High-Tech Enterprise)', '전문화/고도화 중소기업(Specialized and Sophisticated SME)', '1위 제조회사(Manufacturing Single Champion)' 등 중국 정부에서 지정한 칭호를 획득한 수출 회사 중 34%에 해당하는 1만 개 이상의 기업이 캔톤페어에 참가한다. 다양하게 마련된
SINGAPORE, Oct. 14, 2025 -- PRC-Saltillo, a leading provider of AAC (Augmentative and Alternative Communication) devices and support services, is proud to announce the official launch of its wholly owned subsidiary, PRC Saltillo Singapore Pte. Ltd. As PRC-Saltillo enters its 60th year of operation, this expansion marks a new chapter in its mission to empower voices worldwide. Founded in 1966, PRC-Saltillo has been a pioneering force in the industry and one of the few AAC companies led by speech-language pathologists, ensuring clinical relevance and user-centered design.
WASHINGTON, Oct. 14, 2025 -- The International Union for Conservation of Nature (IUCN) issued a decision on October 9, 2025, to retain the "Endangered" status determination for long-tailed macaque ("LTM") monkeys (Macaca fascicularis). The latest issuance by the IUCN follows a 2023 petition filed by the National Association for Biomedical Research (NABR) challenging the IUCN status determination. NABR's petition demonstrates that reviews by Hansen et. al., which the IUCN has used as the basis for its status determinations, misrepresent existing scientific da
XIAN, China, Oct. 13, 2025 -- Natural Field has achieved new continuous research breakthroughs in co-loading liposome technology, with remarkable progress particularly in the development of co-loading Coenzyme Q10 (CoQ10) liposome and co-loading curcumin liposome raw materials. This technology demonstrates strong potential in enhancing the bioavailability, stability, and synergistic effects of active ingredients, opening up new pathways for health support. During this R&D process, Natural Field conducted in-depth exploration into the mechanisms of action and efficacy of co-loading
Autonomous and Manual Kits deliver mobile, layered counter-drone defense, building on 2,500+ systems fielded in over 50 countries WASHINGTON, Oct. 13, 2025 -- DZYNE Technologies today unveiled its new Dronebuster® Vehicle Kits at the Association of the United States Army (AUSA) Annual Meeting in Washington, D.C. The expansion of the combat-proven Dronebuster® line brings mobile counter-UAS protection to vehicles, convoys, and infrastructure – extending capabilities already trusted by forces in over 50 countries, with more than 2,500 units fielded worldwide. "
TORONTO, Oct. 13, 2025 -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary, Visionary Holdings (Asia) Limited, has entered into a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. ("Yike"). The agreement grants GV the worldwide rights to apply Yike's breakthrough stem cell technology, which has demonstrated significant potential in advancing treatments for diabetes and with other regenerativ
BOSTON, Oct. 13, 2025 -- Complete Genomics, a leading innovator in genomic sequencing, today announced at the American Society of Human Genetics Annual Meeting that it has added Houston-based Gene by Gene, a leading genetics laboratory, to its Sequencing Service Provider Program. The Complete Genomics Service Provider Program connects its customers to a network of service providers, offering access to high-quality sequencing services using Complete Genomics DNBSEQ™ sequencing platforms. "We're excited about partnering with Complete Genomics, which we believe will contribut
RESORB Study Marks Major Step Toward U.S. Regulatory Approval and Global Commercialization SEOUL, South Korea, Oct. 13, 2025 -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, today announced the enrollment of the first patient in its U.S. pivotal clinical trial evaluating Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization. This milestone represents a significant advancement in NEXTBIOMEDICAL's U.S. regulatory pathway, following FDA approval of its Investigational Device
CHENGDU, China, Oct. 13, 2025 -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene's lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both the NMPA and the FDA to treat Parkinson's disease (PD). Recently, NouvNeu001 Phase I clinical data were presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS). Excellent safety and tolerability were observed for up to 15 months post-transplantation, no
Headlines: Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1 Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.2 Decreases sample volumes by 100 times vs. current methods for assessing cells and nucleic acids.3 MILFORD, Mass., Oct. 13, 2025 -- Waters Corporation (NYSE: WAT) today unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS)